Tau in Alzheimer’s Disease: Pathological Alterations and an Attractive Therapeutic Target

Abstract

Alzheimer’s disease (AD) is an age-related neurodegenerative disease with two major hallmarks: extracellular amyloid plaques made of amyloid-β (Aβ) and intracellular neurofibrillary tangles (NFTs) of abnormally hyperphosphorylated tau. The number of NFTs correlates positively with the severity of dementia in AD patients. However, there is still no efficient therapy available for AD treatment and prevention so far. A deeper understanding of AD pathogenesis has identified novel strategies for the generation of specific therapies over the past few decades. Several studies have suggested that the prion-like seeding and spreading of tau pathology in the brain may be a key driver of AD. Tau protein is considered as a promising candidate target for the development of therapeutic interventions due to its considerable pathological role in a variety of neurodegenerative disorders. Abnormal tau hyperphosphorylation plays a detrimental pathological role, eventually leading to neurodegeneration. In the present review, we describe the recent research progresses in the pathological mechanisms of tau protein in AD and briefly discuss tau-based therapeutic strategies.

Keywords

Alzheimer’s disease / tau protein / hyperphosphorylation / propagation of tau pathology

References

[1] Grundke-IqbalI, IqbalK, QuinlanM, et al.. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem, 1986, 261(13): 6084-6089

[2] ArriagadaPV, GrowdonJH, Hedley-WhyteET, et al.. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology, 1992, 42(3): 631-639Pt 1

[3] RileyKP, SnowdonDA, MarkesberyWR. Alzheimer’s neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol, 2002, 51(5): 567-577

[4] KopkeE, TungYC, ShaikhS, et al.. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem, 1993, 268(32): 24 374-24 384

[5] Grundke-IqbalI, IqbalK, TungYC, et al.. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA, 1986, 83(13): 4913-4917

[6] AlonsoAC, ZaidiT, Grundke-IqbalI, et al.. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA, 1994, 91(12): 5562-5566

[7] AlonsoA, ZaidiT, NovakM, et al.. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA, 2001, 98(12): 6923-6928

[8] BraakH, Del TrediciK. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol, 2011, 121(2): 171-181

[9] BraakH, BraakE. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol, 1991, 82(4): 239-259

[10] BraakH, BraakE. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging, 1995, 16(3): 271-278

[11] GroberE, DicksonD, SliwinskiMJ, et al.. Memory and mental status correlates of modified Braak staging. Neurobiol Aging, 1999, 20(6): 573-579

[12] AhmedZ, CooperJ, MurrayTK, et al.. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol, 2014, 127(5): 667-683

[13] KumarH, UdgaonkarJB. Mechanistic approaches to understand the prion-like propagation of aggregates of the human tau protein. Biochim Biophys Acta Proteins Proteom, 2019, 1867(10): 922-932

[14] ColinM, DujardinS, Schraen-MaschkeS, et al.. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol, 2020, 139(1): 3-25

[15] GoedertM, EisenbergDS, CrowtherRA. Propagation of Tau Aggregates and Neurodegeneration. Annu Rev Neurosci, 2017, 40: 189-210

[16] GoedertM, SpillantiniMG, JakesR, et al.. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron, 1989, 3(4): 519-526

[17] IqbalK, Alonso AdelC, ChenS, et al.. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta, 2005, 1739(2–3): 198-210

[18] KosikKS, OrecchioLD, BakalisS, et al.. Developmentally regulated expression of specific tau sequences. Neuron, 1989, 2(4): 1389-1397

[19] TakumaH, ArawakaS, MoriH. Isoforms changes of tau protein during development in various species. Brain Res Dev Brain Res, 2003, 142(2): 121-127

[20] GendronTF, PetrucelliL. The role of tau in neurodegeneration. Mol Neurodegener, 2009, 4: 13

[21] MukraschMD, BibowS, KorukottuJ, et al.. Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol, 2009, 7(2): e34

[22] PapasozomenosSC, BinderLI. Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil Cytoskeleton, 1987, 8(3): 210-226

[23] TrojanowskiJQ, SchuckT, SchmidtML, et al.. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem, 1989, 37(2): 209-215

[24] IqbalK, LiuF, GongCX. Recent developments with tau-based drug discovery. Expert Opin Drug Discov, 2018, 13(5): 399-410

[25] ChuD, LiuF. Pathological Changes of Tau Related to Alzheimer’s Disease. ACS Chem Neurosci, 2019, 10(2): 931-944

[26] ChidambaramH, ChinnathambiS. G-Protein Coupled Receptors and Tau-different Roles in Alzheimer’s Disease. Neuroscience, 2020, 438: 198-214

[27] NeddensJ, TemmelM, FlunkertS, et al.. Phosphorylation of different tau sites during progression of Alzheimer’s disease. Acta Neuropathol Commun, 2018, 6(1): 52

[28] AvilaJ, LucasJJ, PerezM, et al.. Role of tau protein in both physiological and pathological conditions. Physiol Rev, 2004, 84(2): 361-384

[29] LaPointeNE, MorfiniG, PiginoG, et al.. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res, 2009, 87(2): 440-451

[30] XiaD, LiC, GotzJ. Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines. Biochim Biophys Acta, 2015, 1852(5): 913-924

[31] AlonsoAC, Grundke-IqbalI, IqbalK. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med, 1996, 2(7): 783-787

[32] WangJZ, Grundke-IqbalI, IqbalK. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci, 2007, 25(1): 59-68

[33] PeiJJ, Grundke-IqbalI, IqbalK, et al.. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer’s disease neurofibrillary degeneration. Brain Res, 1998, 797(2): 267-277

[34] JinN, YinX, YuD, et al.. Truncation and activation of GSK-3beta by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer’s disease. Sci Rep, 2015, 5: 8187

[35] JinN, YinX, GuJ, et al.. Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE. J Biol Chem, 2015, 290(24): 15 219-15 237

[36] Llorach-ParesL, Nonell-CanalsA, AvilaC, et al.. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer’s Disease: A Computational Study. Mar Drugs, 2018, 16(10): 386

[37] HangerDP, AndertonBH, NobleW. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med, 2009, 15(3): 112-119

[38] WuXL, Pina-CrespoJ, ZhangYW, et al.. Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer’s Disease. Chin Med J (Engl), 2017, 130(24): 2978-2990

[39] ReimerL, BetzerC, KofoedRH, et al.. PKR kinase directly regulates tau expression and Alzheimer’s disease-related tau phosphorylation. Brain Pathol, 2020, 27: 1-17

[40] MuralidarS, AmbiSV, SekaranS, et al.. Role of tau protein in Alzheimer’s disease: The prime pathological player. Int J Biol Macromol, 2020, 163: 1599-1617

[41] LiuF, IqbalK, Grundke-IqbalI, et al.. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett, 2002, 530(1–3): 209-214

[42] WoodsYL, CohenP, BeckerW, et al.. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J, 2001, 355(Pt3): 609-615

[43] LiuF, LiangZ, WegielJ, et al.. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J, 2008, 22(9): 3224-3233

[44] SinghTJ, ZaidiT, Grundke-IqbalI, et al.. Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Lett, 1995, 358(1): 4-8

[45] SenguptaA, WuQ, Grundke-IqbalI, et al.. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol Cell Biochem, 1997, 167(1–2): 99-105

[46] GongCX, LiuF, WuG, et al.. Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5. J Neurochem, 2004, 88(2): 298-310

[47] LiuF, Grundke-IqbalI, IqbalK, et al.. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci, 2005, 22(8): 1942-1950

[48] WasikU, SchneiderG, Mietelska-PorowskaA, et al.. Calcyclin binding protein and Siah-1 interacting protein in Alzheimer’s disease pathology: neuronal localization and possible function. Neurobiol Aging, 2013, 34(5): 1380-1388

[49] Diaz-HernandezM, Gomez-RamosA, RubioA, et al.. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem, 2010, 285(42): 32 539-32 548

[50] LiuF, IqbalK, Grundke-IqbalI, et al.. Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer’s disease. J Biol Chem, 2005, 280(3): 1790-1796

[51] LiangZ, LiuF, IqbalK, et al.. Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J Alzheimers Dis, 2008, 13(3): 295-302

[52] QianW, YinX, HuW, et al.. Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer’s disease. J Alzheimers Dis, 2011, 23(4): 617-627

[53] GongCX, ShaikhS, WangJZ, et al.. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem, 1995, 65(2): 732-738

[54] GongCX, SinghTJ, Grundke-IqbalI, et al.. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem, 1993, 61(3): 921-927

[55] WangY, YangR, GuJ, et al.. Cross talk between PI3K-AKT-GSK-3beta and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging, 2015, 36(1): 188-200

[56] QianW, ShiJ, YinX, et al.. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis, 2010, 19(4): 1221-1229

[57] ChuD, TanJ, XieS, et al.. GSK-3beta is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner. J Alzheimers Dis, 2016, 49(2): 365-375

[58] ZilkaN, FilipcikP, KosonP, et al.. Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett, 2006, 580(15): 3582-3588

[59] HasegawaM, Morishima-KawashimaM, TakioK, et al.. Protein sequence and mass spectrometric analyses of tau in the Alzheimer’s disease brain. J Biol Chem, 1992, 267(24): 17 047-17 054

[60] YangLS, Ksiezak-RedingH. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. Eur J Biochem, 1995, 233(1): 9-17

[61] Basurto-IslasG, GuJH, TungYC, et al.. Mechanism of Tau Hyperphosphorylation Involving Lysosomal Enzyme Asparagine Endopeptidase in a Mouse Model of Brain Ischemia. J Alzheimer Dis, 2018, 63(2): 821-833

[62] GamblinTC, ChenF, ZambranoA, et al.. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci USA, 2003, 100(17): 10 032-10 037

[63] ZhangZ, SongM, LiuX, et al.. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat Med, 2014, 20(11): 1254-1262

[64] WischikCM, NovakM, ThogersenHC, et al.. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA, 1988, 85(12): 4506-4510

[65] de CalignonA, FoxLM, PitstickR, et al.. Caspase activation precedes and leads to tangles. Nature, 2010, 464(7292): 1201-1204

[66] ZhouY, ShiJ, ChuD, et al.. Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease. Front Aging Neurosci, 2018, 10: 27

[67] LiL, JiangY, HuW, et al.. Pathological Alterations of Tau in Alzheimer’s Disease and 3xTg-AD Mouse Brains. Mol Neurobiol, 2019, 56(9): 6168-6183

[68] YinH, KuretJ. C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett, 2006, 580(1): 211-215

[69] BerryRW, AbrahaA, LagalwarS, et al.. Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochemistry, 2003, 42(27): 8325-8331

[70] GuJ, XuW, JinN, et al.. Truncation of Tau selectively facilitates its pathological activities. J Biol Chem, 2020, 295(40): 13 812-13 828

[71] GuoT, NobleW, HangerDP. Roles of tau protein in health and disease. Acta Neuropathol, 2017, 133(5): 665-704

[72] JadhavS, KatinaS, KovacA, et al.. Truncated tau deregulates synaptic markers in rat model for human tauopathy. Front Cell Neurosci, 2015, 9: 24

[73] MinSW, ChoSH, ZhouY, et al.. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron, 2010, 67(6): 953-966

[74] CohenTJ, GuoJL, HurtadoDE, et al.. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun, 2011, 2: 252

[75] CookC, StankowskiJN, CarlomagnoY, et al.. Acetylation: a new key to unlock tau’s role in neurodegeneration. Alzheimers Res Ther, 2014, 6(3): 29

[76] TracyT, ClaibornKC, GanL. Regulation of Tau Homeostasis and Toxicity by Acetylation. Adv Exp Med Biol, 2019, 1184: 47-55

[77] CohenTJ, ConstanceBH, HwangAW, et al.. Intrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau Fragmentation. PLoS One, 2016, 11(7): e0158470

[78] JulienC, TremblayC, EmondV, et al.. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol, 2009, 68(1): 48-58

[79] LattanzioF, CarboniL, CarrettaD, et al.. Treatment with the neurotoxic Abeta (25–35) peptide modulates the expression of neuroprotective factors Pin1, Sirtuin 1, and brain-derived neurotrophic factor in SH-SY5Y human neuroblastoma cells. Exp Toxicol Pathol, 2016, 68(5): 271-276

[80] KreppelLK, BlombergMA, HartGW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem, 1997, 272(14): 9308-9315

[81] GaoY, WellsL, ComerFI, et al.. Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem, 2001, 276(13): 9838-9845

[82] HartGW, KreppelLK, ComerFI, et al.. O-GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-phosphorylation and putative roles in protein multimerization. Glycobiology, 1996, 6(7): 711-716

[83] HaltiwangerRS, BlombergMA, HartGW. Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine: polypeptide beta-N-acetylglucosaminyltransferase. J Biol Chem, 1992, 267(13): 9005-9013

[84] LiuF, IqbalK, Grundke-IqbalI, et al.. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci USA, 2004, 101(29): 10 804-10 809

[85] ArnoldCS, JohnsonGV, ColeRN, et al.. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem, 1996, 271(46): 28741-28744

[86] LiuF, ShiJ, TanimukaiH, et al.. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. Brain, 2009, 132(Pt7): 1820-1832

[87] GuJ, JinN, MaD, et al.. Calpain I Activation Causes GLUT3 Proteolysis and Downregulation of O-GlcNAcylation in Alzheimer’s Disease Brain. J Alzheimers Dis, 2018, 62(4): 1737-1746

[88] HershkoA, CiechanoverA. The ubiquitin system. Annu Rev Biochem, 1998, 67: 425-479

[89] KomanderD. The emerging complexity of protein ubiquitination. Biochem Soc Trans, 2009, 37(Pt5): 937-953

[90] PetrucelliL, DicksonD, KehoeK, et al.. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet, 2004, 13(7): 703-714

[91] BabuJR, GeethaT, WootenMW. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem, 2005, 94(1): 192-203

[92] MoriH, KondoJ, IharaY. Ubiquitin is a component of paired helical filaments in Alzheimer’s disease. Science, 1987, 235(4796): 1641-1644

[93] KuzuharaS, MoriH, IzumiyamaN, et al.. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol, 1988, 75(4): 345-353

[94] KellerJN, HanniKB, MarkesberyWR. Impaired proteasome function in Alzheimer’s disease. J Neurochem, 2000, 75(1): 436-439

[95] JohnstonJA, WardCL, KopitoRR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol, 1998, 143(7): 1883-1898

[96] CrippsD, ThomasSN, JengY, et al.. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem, 2006, 281(16): 10 825-10 838

[97] KontaxiC, PiccardoP, GillAC. Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer’s Disease and Related Tauopathies. Front Mol Biosci, 2017, 4: 56

[98] ChuTT, GaoN, LiQQ, et al.. Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation. Cell Chem Biol, 2016, 23(4): 453-461

[99] SchweersO, Schonbrunn-HanebeckE, MarxA, et al.. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem, 1994, 269(39): 24 290-24 297

[100] von BergenM, FriedhoffP, BiernatJ, et al.. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci USA, 2000, 97(10): 5129-5134

[101] LiuK, LiuY, LiL, et al.. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property. Biochim Biophys Acta, 2016, 1862(2): 192-201

[102] NeculaM, KuretJ. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J Biol Chem, 2004, 279(48): 49 694-49 703

[103] QuinnJP, CorbettNJ, KellettKAB, et al.. Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers. J Alzheimers Dis, 2018, 63(1): 13-33

[104] JeganathanS, von BergenM, BrutlachH, et al.. Global hairpin folding of tau in solution. Biochemistry, 2006, 45(7): 2283-2293

[105] FerreonJC, JainA, ChoiKJ, et al.. Acetylation Disfavors Tau Phase Separation. Int J Mol Sci, 2018, 19(5): 1360

[106] YuzwaSA, CheungAH, OkonM, et al.. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J Mol Biol, 2014, 426(8): 1736-1752

[107] ReynoldsMR, BerryRW, BinderLI. Site-specific nitration differentially influences tau assembly in vitro. Biochemistry, 2005, 44(42): 13 997-14 009

[108] FunkKE, ThomasSN, SchaferKN, et al.. Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem J, 2014, 462(1): 77-88

[109] YoshitakeJ, SoedaY, IdaT, et al.. Modification of Tau by 8-Nitroguanosine 3′,5′-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION. J Biol Chem, 2016, 291(43): 22 714-22 720

[110] LuoHB, XiaYY, ShuXJ, et al.. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci USA, 2014, 111(46): 16 586-16 591

[111] Guru KrishnaKumarV, BawejaL, RalhanK, et al.. Carbamylation promotes amyloidogenesis and induces structural changes in Tau-core hexapeptide fibrils. Biochim Biophys Acta Gen Subj, 2018, 1862(12): 2590-2604

[112] RizzuP, Van SwietenJC, JoosseM, et al.. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet, 1999, 64(2): 414-421

[113] Alonso AdelC, MederlyovaA, NovakM, et al.. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem, 2004, 279(33): 34 873-34 881

[114] LuM, KosikKS. Competition for microtubule-binding with dual expression of tau missense and splice isoforms. Mol Biol Cell, 2001, 12(1): 171-184

[115] AdamsSJ, DeTureMA, McBrideM, et al.. Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS One, 2010, 55(5): e10810

[116] MudherA, ColinM, DujardinS, et al.. What is the evidence that tau pathology spreads through prion-like propagation?. Acta Neuropathol Commun, 2017, 5(1): 99

[117] WangY, MandelkowE. Tau in physiology and pathology. Nat Rev Neurosci, 2016, 17(1): 5-21

[118] GiustinianiJ, GuillemeauK, DounaneO, et al.. The FK506-binding protein FKBP52 in vitro induces aggregation of truncated Tau forms with prion-like behavior. FASEB J, 2015, 29(8): 3171-3181

[119] WischikCM, SchelterBO, WischikDJ, et al.. Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development. J Alzheimers Dis, 2018, 62(3): 1287-1303

[120] LeeVM, GoedertM, TrojanowskiJQ. Neurodegenerative tauopathies. Annu Rev Neurosci, 2001, 24: 1121-1159

[121] MamunAA, UddinMS, MathewB, et al.. Toxic tau: structural origins of tau aggregation in Alzheimer’s disease. Neural Regen Res, 2020, 15(8): 1417-1420

[122] HolmesBB, DeVosSL, KfouryN, et al.. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA, 2013, 110(33): E3138-3147

[123] FalconB, CavalliniA, AngersR, et al.. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem, 2015, 290(2): 1049-1065

[124] MaizaA, ChantepieS, VeraC, et al.. The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration. FEBS Lett, 2018, 592(23): 3806-3818

[125] FrostB, JacksRL, DiamondMI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem, 2009, 284(19): 12 845-12 852

[126] ShafieiSS, Guerrero-MunozMJ, Castillo-CarranzaDL. Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. Front Aging Neurosci, 2017, 9: 83

[127] TellingGC, ParchiP, DeArmondSJ, et al.. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science, 1996, 274(5295): 2079-2082

[128] DujardinS, ComminsC, LathuiliereA, et al.. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat Med, 2020, 26(8): 1256-1263

[129] HuW, ZhangX, TungYC, et al.. Hyperphosphorylation determines both the spread and the morphology of tau pathology. Alzheimers Dement, 2016, 12(10): 1066-1077

[130] MiaoJ, ShiR, LiL, et al.. Pathological Tau from Alzheimer’s Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo. Front Aging Neurosci, 2019, 11: 34

[131] DemaegdK, SchymkowitzJ, RousseauF. Transcellular Spreading of Tau in Tauopathies. Chembiochem, 2018, 19(23): 2424-2432

[132] BrunelloCA, MerezhkoM, UronenRL, et al.. Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci, 2020, 77(9): 1721-1744

[133] IttnerLM, GotzJ. Amyloid-beta and tau—a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci, 2011, 12(2): 65-72

[134] KeYD, SuchowerskaAK, van der HovenJ, et al.. Lessons from tau-deficient mice. Int J Alzheimers Dis, 2012, 2012: 873

[135] CongdonEE, SigurdssonEM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol, 2018, 14(7): 399-415

[136] WittrupA, LiebermanJ. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet, 2015, 16(9): 543-552

[137] ZuckermanJE, DavisME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov, 2015, 14(12): 843-856

[138] Santa-MariaI, AlanizME, RenwickN, et al.. Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest, 2015, 125(2): 681-686

[139] Banzhaf-StrathmannJ, BenitoE, MayS, et al.. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. EMBO J, 2014, 33(15): 1667-1680

[140] SmithPY, Hernandez-RappJ, JolivetteF, et al.. miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum Mol Genet, 2015, 24(23): 6721-6735

[141] LiuW, ZhaoJ, LuG. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer’s disease. Biochem Biophys Res Commun, 2016, 478(2): 852-857

[142] CoreyDR. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci, 2017, 20(4): 497-499

[143] FinkelRS, ChiribogaCA, VajsarJ, et al.. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet, 2016, 388(10063): 3017-3026

[144] JadhavS, AvilaJ, SchollM, et al.. A walk through tau therapeutic strategies. Acta Neuropathol Commun, 2019, 7(1): 22

[145] NobleW, Jimenez-SanchezM, Perez-NievasBG, et al.. Considerations for future tau-targeted therapeutics: can they deliver?. Expert Opin Drug Discov, 2020, 15(3): 265-267

[146] LevensonJM, SchroeterS, CarrollJC, et al.. NPT088 reduces both amyloid-beta and tau pathologies in transgenic mice. Alzheimers Dement (N Y), 2016, 2(3): 141-155

[147] SeidlerPM, BoyerDR, RodriguezJA, et al.. Structure-based inhibitors of tau aggregation. Nat Chem, 2018, 10(2): 170-176

[148] JuckerM, WalkerLC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature, 2013, 501(7465): 45-51

[149] PoolerAM, PolydoroM, WegmannS, et al.. Propagation of tau pathology in Alzheimer’s disease: identification of novel therapeutic targets. Alzheimers Res Ther, 2013, 5(5): 49

[150] BakotaL, BrandtR. Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease. Drugs, 2016, 76(3): 301-313

[151] MedinaM. An Overview on the Clinical Development of Tau-Based Therapeutics. Int J Mol Sci, 2018, 19(4): 1160

[152] BrundenKR, ZhangB, CarrollJ, et al.. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci, 2010, 30(41): 13 861-13 866

[153] ZhangB, CarrollJ, TrojanowskiJQ, et al.. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci, 2012, 32(11): 3601-3611

[154] BoxerAL, QureshiI, AhlijanianM, et al.. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol, 2019, 18(6): 549-558

[155] DaiCL, ChenX, KazimSF, et al.. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna), 2015, 122(4): 607-617

[156] DaiCL, TungYC, LiuF, et al.. Tau passive immunization inhibits not only tau but also Abeta pathology. Alzheimers Res Ther, 2017, 9(1): 1

[157] DaiCL, HuW, TungYC, et al.. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 x Tg-AD mice. Alzheimers Res Ther, 2018, 10(1): 13

[158] FlachK, HilbrichI, SchiffmannA, et al.. Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem, 2012, 287(52): 43 223-43 233

[159] Guerrero-MunozMJ, GersonJ, Castillo-CarranzaDL. Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease. Front Cell Neurosci, 2015, 9: 464

[160] GersonJE, SenguptaU, KayedR. Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo. Methods Mol Biol, 2017, 1523: 141-157